Intech Investment Management LLC Purchases New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Intech Investment Management LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 32,395 shares of the biopharmaceutical company’s stock, valued at approximately $644,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 12.1% during the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after purchasing an additional 860,244 shares during the period. Dimensional Fund Advisors LP increased its stake in Catalyst Pharmaceuticals by 9.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock worth $46,479,000 after acquiring an additional 263,099 shares during the period. Pacer Advisors Inc. raised its holdings in Catalyst Pharmaceuticals by 130,918.8% in the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after acquiring an additional 2,965,310 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Catalyst Pharmaceuticals by 15.2% during the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after acquiring an additional 287,300 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Catalyst Pharmaceuticals by 1.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,219,418 shares of the biopharmaceutical company’s stock worth $19,439,000 after purchasing an additional 22,860 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock opened at $22.07 on Friday. The company’s 50 day moving average price is $21.26 and its two-hundred day moving average price is $18.76. The firm has a market capitalization of $2.63 billion, a P/E ratio of 18.70, a P/E/G ratio of 3.44 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $13.00 and a fifty-two week high of $24.27.

Insider Buying and Selling

In other news, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the sale, the insider now directly owns 51,391 shares in the company, valued at approximately $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the company. StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Stephens started coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 target price for the company. Truist Financial upped their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. Finally, Citigroup upped their target price on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Catalyst Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $31.14.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.